SCHEMBL4257968

SCHEMBL4257968

C=CCB(CC=C)CC=C.[NaH]

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL498964 0.96 TSHR (0.33) TSHRALDH1A1
SCHEMBL6570628 0.92 TSHR (0.31) TSHRALDH1A1
SCHEMBL721744 0.92 TSHR (0.31) TSHRALDH1A1
SCHEMBL1268551 0.75
SCHEMBL3738689 0.74
SCHEMBL8966736 0.70 TSHR (0.38) TSHRALDH1A1
SCHEMBL1931674 0.70 TSHR (0.33) TSHRALDH1A1
SCHEMBL27140 0.67
SCHEMBL370393 0.64
SCHEMBL7695888 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4294814-A1 METAL COMPLEXES HAVING 4-H, 6-H OR 8-H DIHYDROAZULENYL LIGANDS AND USE THEREOF Umicore AG & Co. KG (DE) 2023-12-27 EP disclosed
CN-117003630-A Methods and intermediates for preparing carboprostacyclin analogs 佳和桂科技股份有限公司 2023-11-07 CN disclosed
CN-116917295-A Metal complexes with 4-H, 6-H or 8-H-dihydroazulene ligands and uses thereof 优米科尔股份公司及两合公司 2023-10-20 CN disclosed
EP-2010539-B1 STEREOSELECTIVE REDUCTION OF A MORPHINONE NEKTAR THERAPEUTICS (US) 2017-06-14 EP disclosed
US-8563726-B2 Stereoselective reduction of a morphinone NEKTAR THERAPEUTICS (US) 2013-10-22 US disclosed
US-20130018190-A1 STEREOSELECTIVE REDUCTION OF A MORPHINONE NEKTAR THERAPEUTICS (US) 2013-01-17 US disclosed
US-8183376-B2 Stereoselective reduction of a morphinone NEKTAR THERAPEUTICS (US) 2012-05-22 US disclosed
EP-0876295-B1 METHODS FOR SYNTHESIS OF NANOSTRUCTURED OXIDES AND HYDROXIDES UNIV CONNECTICUT (US) 2009-10-07 EP disclosed
US-20090221766-A1 STEREOSELECTIVE REDUCTION OF A MORPHINONE NEKTAR THERAPEUTICS AL, CORPORATION (US) 2009-09-03 US disclosed
EP-2010539-A2 STEREOSELECTIVE REDUCTION OF A MORPHINONE Nektar Therapeutics AL, Corporation (US) 2009-01-07 EP disclosed
US-5137881-A Anticholesterol, antilipemic agents BAYER AKTIENGESELLSCHAFT (DE) 1992-08-11 US disclosed
US-5120782-A Treatment of hyperlipoproteinaemia, lipoproteinaemia and arteriosclerosis BAYER AKTIENGESELLSCHAFT (DE) 1992-06-09 US disclosed
US-5076829-A SUBSTITUTED 2,3-EPOXY-5-CYCLOHEXENONE DERIVATIVES, AND FUNGICIDES AND HERBICIDES CONTAINING SAME BASF AKTIENGESELLSCHAFT (DE) 1991-12-31 US disclosed
US-5075311-A Anticholesterol agents BAYER AKTIENGESELLSCHAFT (DE) 1991-12-24 US disclosed
US-5064841-A HMG-COA reductase-inhibiting imino-substituted pyridines BAYER AKTIENGESELLSCHAFT (DE) 1991-11-12 US disclosed
US-5034399-A Enzyme inhibitors, anticholesterol agents or antilipemic agents BAYER AKTIENGESELLSCHAFT (DE) 1991-07-23 US disclosed
US-5032602-A Inhibiting HMG-CoA reductase with novel substituted 2-pyridones and pyrid-2-thiones BAYER AKTIENGESELLSCHAFT (DE) 1991-07-16 US disclosed
US-4988711-A HMG-CoA reductare-inhibiting N-substituted N-amino-pyrroles BAYER AKTIENGESELLSCHAFT (DE) 1991-01-29 US disclosed
US-4973598-A Substituted imidazolinones and imidazolinethiones BAYER AKTIENGESELLSCHAFT (DE) 1990-11-27 US disclosed
US-4000273-A METHOD FOR THE CONTROL OF FERTILITY RICHARDSON-MERRELL INC. (US) 1976-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018190-A1 STEREOSELECTIVE REDUCTION OF A MORPHINONE SORD, ADH1C, ADH1A TSHR 4662/4885ALDH1A1 57/4885
US-20090221766-A1 STEREOSELECTIVE REDUCTION OF A MORPHINONE SORD, ADH1C, ADH1A TSHR 4662/4885ALDH1A1 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.